Ablexis, LLC

Ablexis, LLC is a biotechnology startup that offers the AlivaMab® Mouse platform, a suite of transgenic mouse strains designed for human therapeutic antibody discovery. The platform is tailored for various applications across antibody drug discovery, including the development of highest quality IgGs, single-domain VH, multispecifics, ADCs, CARs, TCRm, and other modalities. The AlivaMab Mouse strains are highly regarded for their ability to generate drug-like antibodies with broad combinatorial and somatic diversities, high affinities, specificity, and excellent developability properties. The company was founded in 2009 and is based in the United States. Ablexis, LLC received a significant $12.00M Series A investment on 02 June 2010 from Third Rock Ventures and Pfizer Venture Investments. The company's clients include major pharmas, public and private biotechs, and leading academic institutions, and the derived antibodies are utilized in clinical development across various formats. Additionally, the company's sister entity, AlivaMab Biologics, provides services in antibody drug discovery, engineering, and protein sciences. For those interested in licensing the AlivaMab Mouse, they may reach out to [email protected] or visit the company's website at www.ablexis.com for further information.